How Do Sport Medicine Doctors Make Return-to-Play Decisions?

Three-Step Process Provides Guidance on Complex Decisions on Return to Competition after Athletic Injuries

Newswise — When is it appropriate for an injured athlete to return to competition? A new three-step framework provides team physicians and other sport medicine clinicians with guidance on making complex decisions about return to play, reported in the September Clinical Journal of Sport Medicine. The journal is published by Lippincott Williams & Wilkins, a part of Wolters Kluwer Health, a leading provider of information and business intelligence for students, professionals, and institutions in medicine, nursing, allied health, and pharmacy.

The decision-based model "helps clarify the processes that clinicians use consciously and subconsciously when making return-to-play decisions," the researchers write. A panel of U.S. and Canadian sport medicine clinicians and researchers developed the model, based on a synthesis of previous literature. The lead author was David W. Creighton, M.S., of Stanford University School of Medicine. Model Provides Structured Framework for Return-to-Play DecisionsThe model seeks to define the many factors that can affect decisions regarding return to competition after athletic injuries. The three-step process begins with Evaluation of Health Status: how much healing has occurred and how close to "normal" the injured tissue is. The evaluation includes not only medical factors like symptoms, range of motion, or x-rays, but also the athlete's psychological state—his or her "readiness" or "confidence" to return to play. The potential seriousness of the injury is another factor. "The evaluation of health status is very different for a concussion versus an ankle sprain," the authors write.

The next step is Evaluation of Participation Risk—the risk that the athlete will be injured again if he or she returns to play too soon. Previous injury is associated with up to a 4-fold increase in the risk of reinjury. The type of sport is one key factor—contact sports like basketball carry a higher risk of acute injuries, yet athletes in noncontact sports like running have the potential for disabling overuse injuries. Other factors may include the position played, the level of competition, and the ability to protect the injury.

The third and most complex step is Decision Modification. It calls to attention the many and varied situations and circumstances that may affect the final decision on return-to-play. For example, decisions may be different if the injury occurs in the preseason before a playoff game. The athlete's desire to compete may place pressure on the physician, while coaches, the athlete's family, and even sponsors or the media may be sources of external pressure. "Potential conflicts of interest arise when the team's best interests and the athletes' best interests are not aligned," the researchers write.

Despite its central importance in sport medicine, there is little scientific evidence to guide the process of making return-to-play decisions. The authors hope their proposed model will provide "structure and transparency" in making these often-complex decisions. They emphasize the need for more research to clarify each of the three steps in the process. Ultimately, they hope the model will lead address the need for "evidence-based rationales for return-to-play decision making."

In an accompanying editorial, Dr. Ian Shrier of McGill University, Montreal, and colleagues give a clinical perspective on the "social context" of return-to-play decision making. They believe the new model can provide a much-needed formal structure and process to minimize potential conflicts between the physician, coach, athletes, and others involved. "Given that return-to-play decisions represent a fundamental element of sport medicine practice," the authors conclude, "it is time that we learn more about how, when where, why, and by whom these decisions are made in different sport settings and how such processes can be improved."

About Clinical Journal of Sport MedicineClinical Journal of Sport Medicine is an international refereed journal published for clinicians with a primary interest in sports medicine practice. The journal publishes original research and reviews covering diagnostics, therapeutics, and rehabilitation in healthy and physically challenged individuals of all ages and levels of sport and exercise participation. CJSM is the official journal of the American Medical Society for Sports Medicine, the American Osteopathic Academy of Sports Medicine, the Australasian College of Sports Physicians, and the Canadian Academy of Sport Medicine.

About Lippincott Williams & Wilkins Lippincott Williams & Wilkins (LWW) is a leading international publisher for healthcare professionals and students with nearly 300 periodicals and 1,500 books in more than 100 disciplines publishing under the LWW brand, as well as content-based sites and online corporate and customer services.

LWW is part of Wolters Kluwer Health, a leading provider of information and business intelligence for students, professionals and institutions in medicine, nursing, allied health and pharmacy. Major brands include traditional publishers of medical and drug reference tools and textbooks, such as Lippincott Williams & Wilkins and Facts & Comparisons®; and electronic information providers, such as Ovid®, UpToDate®, Medi-Span® and ProVation® Medical.

Wolters Kluwer Health is part of Wolters Kluwer, a market-leading global information services company. Professionals in the areas of legal, business, tax, accounting, finance, audit, risk, compliance, and healthcare rely on Wolters Kluwer’s leading, information-enabled tools and solutions to manage their business efficiently, deliver results to their clients, and succeed in an ever more dynamic world.

Wolters Kluwer has 2009 annual revenues of €3.4 billion ($4.8 billion), employs approximately 19,300 people worldwide, and maintains operations in over 40 countries across Europe, North America, Asia Pacific, and Latin America. Wolters Kluwer is headquartered in Alphen aan den Rijn, the Netherlands. Its shares are quoted on Euronext Amsterdam (WKL) and are included in the AEX and Euronext 100 indices.